Search results
Results from the WOW.Com Content Network
Cytomegalovirus (CMV) (from cyto-'cell' via Greek κύτος kútos - 'container' + μέγας mégas 'big, megalo-' + -virus via Latin vīrus 'poison') is a genus of viruses in the order Herpesvirales, in the family Herpesviridae, [3] in the subfamily Betaherpesvirinae. Humans and other primates serve as natural hosts.
A study published in 2009 links infection with CMV to high blood pressure in mice, and suggests that the result of CMV infection of blood vessel endothelium in humans is a major cause of atherosclerosis. [51] Researchers also found that when the cells were infected with CMV, they created renin, a protein known to contribute to high blood pressure.
The infection is spread by saliva, urine, respiratory droplets, sexual contact, and blood transfusions. Most people are exposed to the virus in their lifetime, but it usually produces mild or no symptoms in healthy people. [citation needed] However, serious CMV infections can occur in people with weakened immune systems.
There is no need to either screen for CMV or exclude CMV-excreting children from schools or institutions because the virus is frequently found in many healthy children and adults. Treatment with hyperimmune globulin in mothers with primary CMV infection has been shown to be effective in preventing congenital disease in several studies.
For premium support please call: 800-290-4726 more ways to reach us
CMV, a common virus, that can be asymptomatic can cause birth defects, deaths when babies are born with it. No vaccine yet. Awareness and prevention are best.
Cytomegalic inclusion body disease (CIBD) also known as cytomegalic inclusion disease (CID) is a series of signs and symptoms caused by cytomegalovirus infection, toxoplasmosis or other rare infections such as herpes or rubella viruses. It can produce massive calcification of the central nervous system, and often the kidneys. [1]
A Cytomegalovirus vaccine is a vaccine to prevent cytomegalovirus (CMV) infection or curb virus re-activation (symptomatic flare-ups) in persons already infected. Challenges in developing a vaccine include adeptness of CMV in evading the immune system and limited animal models. [1]